



09/541795

1 for CofC

PATENT
Customer No. 22,852
Attorney Docket No. 09095.0005-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No.: 6,878,700 B1)
)
Inventors: James **LINK** *et al.*)
)
Issue Date.: April 12, 2005)
)
For: CELL ADHESION-INHIBITING)
ANTIINFLAMMATORY AND)
IMMUNE-SUPPRESSIVE)
COMPOUNDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CERTIFICATE OF CORRECTION

Pursuant to 35 U.S.C. § 254, and 37 C.F.R. § 1.322, this is a request for a Certificate of Correction in the above-identified patent. The mistakes identified in the appended Form occurred through the fault of the Patent Office, as clearly disclosed by the records of the application which matured into this patent.

Two (2) copies of PTO Form 1050 are appended. The complete Certificate of Correction involves four (4) pages. Issuance of the Certificate of Correction containing the correction is earnestly requested.

Please charge any required fees not included herewith to our Deposit Account

No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: May 4, 2005

By: *Maria Bautista*
Maria T. Bautista
Reg. No. 52,516

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 6,878,700 B1

DATED: April 12, 2005

INVENTORS: James Link, Gang Liu, ZhongHua Pei, Tom von Geldern, Martin Winn, Zhili Xin, Steven A. Boyd, Giu-Dong Zhu, Jennifer C. Freeman, Indrani W. Gunawardana, Michael A. Staeger, Hwan-Soo Jae, John K. Lynch, and Sheldon Wang

It is hereby certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page, Item (57), in the Abstract, line 2, "immunune" should read --immune--.

In claim 1, column 221, line 23, "hydrogen." should read --hydrogen,--.

In claim 1, column 221, line 24, "R₁" should read --R₁--.

In claim 3, column 225, lines 18-19,

"(2-isop-Propylphenyl)[2-nitro-4-(E-((4-acetyl piperazin-1-yl carbonyl)ethenyl)phenyl)sulfide;" should read

--(2-iso-Propylphenyl)[2-nitro-4-(E-((4-acetyl piperazin-1-yl carbonyl)ethenyl)phenyl)sulfide;--.

In claim 3, column 225, lines 61-62,

"(2-Methoxyphenyl)[2-chloro-4-(E-[(morpholin-1-yl)carbonyl] ethenyl)phenyl)sulfide;" should read

--(2-Methoxyphenyl)-[2-chloro-4-(E-[(morpholin-1-yl)carbonyl] ethenyl)phenyl)sulfide;--.

In claim 3, column 226, lines 36-37,

"(2-Fluorophenyl)[2-nitro-4-(E-((4-acetyl piperazin-1-yl) carbonyl)ethenyl)phenyl)sulfide;" should read

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Patent No. 6,878,700 B1

No. of additional copies
@ .30¢ per page

--(2-Fluorophenyl)[2-nitro-4-(E-((4-acetylpiperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 227, lines 18-20,

"(2-isopropylphenyl)[2-nitro-4-(E-((3-(pyridine-4-methylaminocarbonyl)piperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(2-Isopropylphenyl)[2-nitro-4-(E-((3-(pyridine-4-methylaminocarbonyl)piperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 228, lines 11-13,

"(3-((2(1-Morpholinyl)ethyl)aminocarbonyl)phenyl)[2-nitro-4-(E-((4-acetylpiperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(3-((2-(1-Morpholinyl)ethyl)aminocarbonyl)phenyl)[2-nitro-4-(E-((4-acetylpiperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 228, lines 14-16,

"(2-isopropylphenyl)[2-nitro-4-(E-((3-hydroxymethyl-4-tert-butoxycarbonylpiperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(2-Isopropylphenyl)[2-nitro-4-(E-((3-hydroxymethyl-4-tert-butoxycarbonylpiperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 228, lines 53-55,

"(2-isopropylphenyl)[2-nitro-4-(E-((2-carbomethoxy-4-methoxycarbonylpiperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(2-Isopropylphenyl)[2-nitro-4-(E-((2-carbomethoxy-4-methoxycarbonylpiperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 229, lines 32-33,

"(2-Isopropylphenyl)[2-nitro-4-(E-((4-((1-propen-2-oxo)carbonyl)piperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Patent No. 6,878,700 B1

No. of additional copies
@ .30¢ per page

--(2-Isopropylphenyl)[2-nitro-4-(E-((4-((1-propen-2-oxy)carbonyl)piperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 229, lines 41-42,

"(2-Isopropylphenyl)[2-nitro-4-(E-((4-(pyrimidin-2-y)piperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read
--(2-Isopropylphenyl)[2-nitro-4-(E-((4-(pyrimidin-2-yl)piperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 230, lines 46-47,

"(Benzodioxan-6-yl)[2-nitro-4-(E-((4-carboxamidopiperidin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(Benzodioxan-6-yl)[2-nitro-4-(E-((4-carboxamidopiperidin-1-yl)carbonyl)ethenyl)phenyl]sulfide;

In claim 3, column 230, lines 50-52,

"(2-isopropylphenyl)[2-nitro-4-(E-((syn-3,5-dimethylmorpholin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(2-Isopropylphenyl)[2-nitro-4-(E-((syn-3,5-dimethylmorpholin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 233, lines 52-54,

"(Benzodioxan-6-yl)[2-trifluoromethyl-4-(E-((3-((ethanesulfonylamino)carbonyl)piperidin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(Benzodioxan-6-yl)[2-trifluoromethyl-4-(E-((3-((ethanesulfonylamino)carbonyl)piperidin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 233, lines 61-62,

"(Benzodioxan-6-yl)[2-trifluoromethyl-4-(E-((2-tetrazol-5yl)morpholin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(Benzodioxan-6-yl)[2-trifluoromethyl-4-(E-((2-tetrazol-5-yl)morpholin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Patent No. 6,878,700 B1

No. of additional copies
@ .30¢ per page

In claim 3, column 233, lines 63-64,

"(2-Isopropylphenyl)[2-nitro-4-(E-((2-butyl-5-(tetrazol-5-yl)morpholin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(2-Isopropylphenyl)[2-nitro-4-(E-((2-butyl-5-(tetrazol-5-yl)morpholin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 234, lines 10-11,

"(Benzodioxan-6-yl)[2-chloro-4-(E-((3-carboxypiperidin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(Benzodioxan-6-yl)[2-chloro-4-(E-((3-carboxypiperidin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 234, lines 12-14,

"(2-(and 3-)(Aminomethyl)-benzodioxan-6-yl)[2-trifluoromethyl-4-(E-((3-(2-oxopyrrolidin-1-yl)prop-1-ylamino)carbonyl)ethenyl)phenyl]sulfide;" should read

--(2-(and 3-)(Aminomethyl)-benzodioxan-6-yl)[2-trifluoromethyl-4-(E-((3-(2-oxopyrrolidin-1-yl)prop-1-ylamino)carbonyl)ethenyl)phenyl]sulfide;--.

In claim 3, column 234, lines 35-36,

"(2-Methoxyphenyl-[2,3-dimethyl-4-(E-[(morpholin-1-yl)carbonyl]ethenyl)phenyl]sulfide;" should read

--(2-Methoxyphenyl-[2,3-dimethyl-4-(E-[(morpholin-1-yl)carbonyl]ethenyl)phenyl]sulfide;--.

In claim 3, column 236, lines 43-44,

"(2-Methoxyphenyl)[2,3-dichloro-4-(4-furoylpiperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;" should read

--(2-Methoxyphenyl)[2,3-dichloro-4-((4-furoylpiperazin-1-yl)carbonyl)ethenyl)phenyl]sulfide;--.

MAILING ADDRESS OF SENDER

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Patent No. 6,878,700 B1

No. of additional copies
@ .30¢ per page